Market Cap 106.35M
Revenue (ttm) 0.00
Net Income (ttm) -5.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 233
Avg Vol 3,250
Day's Range N/A - N/A
Shares Out 8.39M
Stochastic %K 0%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 626 415 1488
Address:
750 Royal Oaks Drive, Suite 106, Monrovia, United States
yes3
yes3 Oct. 19 at 3:37 AM
$EXOZ whats the TAM?
1 · Reply
Slack_Capital
Slack_Capital Oct. 17 at 7:46 PM
$EXOZ Another podcast interview! https://www.youtube.com/watch?v=-RIq1VXORfU
0 · Reply
Slack_Capital
Slack_Capital Oct. 9 at 8:54 PM
$EXOZ Supportive Investment Drivers 📈✅ - Holds a comprehensive patent portfolio and was the first to develop an Exozyme biomanufacturing platform, creating a strong barrier of entry for competitors. - Several undisclosed compounds are being actively developed, targeting multi-billion-dollar opportunities, particularly in the high-value nutraceutical and pharmaceutical sectors. - Secured numerous government grants, reflecting recognition of the platform’s strategic importance in advancing the US biotechnology sector. - High-profile industry executives have joined the team, reflecting confidence in the platform’s capabilities and increasing the likelihood of commercial success. - Maintains a disciplined capital approach, prioritising high-impact projects and operational efficiency prior to scaling its platform. https://www.slack-capital.com/p/exozymes-snapshot-investment-case
1 · Reply
Slack_Capital
Slack_Capital Oct. 8 at 6:40 AM
$EXOZ Recieved a new investor question a few days ago in regards to @eXoZymes competitors in the 'cell-free' enzyme space... My answer is below: So ‘Cell-free’ enzymatic systems aren’t new, they’ve been used for decades. For example laundry detergents use a single enzymatic step to break down dirt, blood etc in our clothes. Some companies can string 5 biocatalysis steps together however beyond that most platforms start failing. Debut Bio is slightly different in that substrates flow from one enzyme bioreactor to another. Each bioreactor is fine tuned to that enzymes optimal pH, temperature, solvent and synthesis time. So this means you need a dedicated bioreactor for every step, which adds complexity and scale-up costs compared to @eXoZymes single bioreactor solution. There is also little detail on how extensively Debut engineers its enzymes to enhance stability, activity, selectivity etc. which improves production purity, yields and titers.
1 · Reply
B2iDigital
B2iDigital Oct. 6 at 5:42 PM
The B2i Digital team is pleased to introduce eXoZymes (Nasdaq: $EXOZ) Inc. as a new B2i Digital Featured Company. A full company profile will be available soon at https://b2idigital.com/featured-companies eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through its proprietary exozyme platform. The company has developed AI-engineered enzymes that operate outside living cells to transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals, offering a scalable and commercially viable alternative to traditional petrochemical production methods, natural extraction, or synthetic biology. Founded on technology validated through multiple peer-reviewed publications in Nature Communications and Nature Chemical Biology, eXoZymes focuses on high-value, low-volume products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel. The company recently demonstrated its platform’s capabilities by achieving gram-scale production of NCT (a nutraceutical compound) with over 99% purity in just five months, showcasing the speed and efficiency of its cell-free approach. With $1.4 million in grant income through Q2 2025 from sources including NIH, NSF, and BioMADE, eXoZymes is advancing multiple projects including its lead NCT program targeting the non-alcoholic fatty liver disease (NAFLD) treatment market, estimated at $21 billion. The company’s BioClick platform, supported by NIH, accelerates enzyme engineering through high-throughput screening capabilities and novel ways of implementing AI. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, VP of Research and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, Ph.D., VP of Business Development; and Lasse H. Görlitz, VP of Communications & IR. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com
1 · Reply
Slack_Capital
Slack_Capital Oct. 1 at 8:03 PM
Michael Heltzen, CEO of @eXoZymes, shares a fantastic introduction to the company in this new podcast episode A great entry point for understanding the science, the strategy and the impact behind $EXOZ Give it a listen on your next evening walk! 🎧 https://www.bc-la.org/podcast/episode/1e32e528/revolutionizing-biotechnology-with-exozymes-michael-heltzen-ceo-of-exozymes
0 · Reply
Slack_Capital
Slack_Capital Sep. 30 at 8:48 PM
$EXOZ @eXoZymes is establishing itself as cell-free biomanufacturing's thought leader: - Leadership/Technical committee appointment to BioMade - eXoZymes selected as core industry partner for $9M grant to advance cell-free biomanufacturing - eXoZymes is crafting the language, terminology and standards as first movers (GEN Tech) - Yannick Bombel, NREL, reached out to Tyler Korman after releasing the significance of the tech - Seemingly the only global Exozyme system company - Holds all the core patents and has numerous trade secrets https://exozymes.com/blog/biomade-thought-leaders?utm_campaign=24163114-202509%20BioMADE%20thought%20leadership
0 · Reply
eXoZymes
eXoZymes Sep. 26 at 1:41 PM
0 · Reply
Slack_Capital
Slack_Capital Sep. 25 at 9:57 PM
$EXOZ Just released a snapshot investment report on @eXoZymes 🔬🧪💊 It covers the latest key developments and a speculative roadmap with market cap projections until 2028 https://slack-capital.com/p/exozymes-snapshot-investment-case If you missed my inital report, this post offers a fantastic investment intro
0 · Reply
Slack_Capital
Slack_Capital Sep. 23 at 10:15 PM
$EXOZ sell side looks to be drying up and long-term shareholders are holding tight 🔥 @exozymes is in the final stages of deal negotiations with 3 parties, so when the first commercial agreement lands, the share price could have a dramatic re-rate!
0 · Reply
Latest News on EXOZ
eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today

Aug 12, 2025, 4:50 PM EDT - 2 months ago

eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today


eXoZymes Provides Fourth Quarter and Full Year 2024 Update

Apr 2, 2025, 4:05 PM EDT - 7 months ago

eXoZymes Provides Fourth Quarter and Full Year 2024 Update


yes3
yes3 Oct. 19 at 3:37 AM
$EXOZ whats the TAM?
1 · Reply
Slack_Capital
Slack_Capital Oct. 17 at 7:46 PM
$EXOZ Another podcast interview! https://www.youtube.com/watch?v=-RIq1VXORfU
0 · Reply
Slack_Capital
Slack_Capital Oct. 9 at 8:54 PM
$EXOZ Supportive Investment Drivers 📈✅ - Holds a comprehensive patent portfolio and was the first to develop an Exozyme biomanufacturing platform, creating a strong barrier of entry for competitors. - Several undisclosed compounds are being actively developed, targeting multi-billion-dollar opportunities, particularly in the high-value nutraceutical and pharmaceutical sectors. - Secured numerous government grants, reflecting recognition of the platform’s strategic importance in advancing the US biotechnology sector. - High-profile industry executives have joined the team, reflecting confidence in the platform’s capabilities and increasing the likelihood of commercial success. - Maintains a disciplined capital approach, prioritising high-impact projects and operational efficiency prior to scaling its platform. https://www.slack-capital.com/p/exozymes-snapshot-investment-case
1 · Reply
Slack_Capital
Slack_Capital Oct. 8 at 6:40 AM
$EXOZ Recieved a new investor question a few days ago in regards to @eXoZymes competitors in the 'cell-free' enzyme space... My answer is below: So ‘Cell-free’ enzymatic systems aren’t new, they’ve been used for decades. For example laundry detergents use a single enzymatic step to break down dirt, blood etc in our clothes. Some companies can string 5 biocatalysis steps together however beyond that most platforms start failing. Debut Bio is slightly different in that substrates flow from one enzyme bioreactor to another. Each bioreactor is fine tuned to that enzymes optimal pH, temperature, solvent and synthesis time. So this means you need a dedicated bioreactor for every step, which adds complexity and scale-up costs compared to @eXoZymes single bioreactor solution. There is also little detail on how extensively Debut engineers its enzymes to enhance stability, activity, selectivity etc. which improves production purity, yields and titers.
1 · Reply
B2iDigital
B2iDigital Oct. 6 at 5:42 PM
The B2i Digital team is pleased to introduce eXoZymes (Nasdaq: $EXOZ) Inc. as a new B2i Digital Featured Company. A full company profile will be available soon at https://b2idigital.com/featured-companies eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through its proprietary exozyme platform. The company has developed AI-engineered enzymes that operate outside living cells to transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals, offering a scalable and commercially viable alternative to traditional petrochemical production methods, natural extraction, or synthetic biology. Founded on technology validated through multiple peer-reviewed publications in Nature Communications and Nature Chemical Biology, eXoZymes focuses on high-value, low-volume products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel. The company recently demonstrated its platform’s capabilities by achieving gram-scale production of NCT (a nutraceutical compound) with over 99% purity in just five months, showcasing the speed and efficiency of its cell-free approach. With $1.4 million in grant income through Q2 2025 from sources including NIH, NSF, and BioMADE, eXoZymes is advancing multiple projects including its lead NCT program targeting the non-alcoholic fatty liver disease (NAFLD) treatment market, estimated at $21 billion. The company’s BioClick platform, supported by NIH, accelerates enzyme engineering through high-throughput screening capabilities and novel ways of implementing AI. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, VP of Research and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, Ph.D., VP of Business Development; and Lasse H. Görlitz, VP of Communications & IR. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com
1 · Reply
Slack_Capital
Slack_Capital Oct. 1 at 8:03 PM
Michael Heltzen, CEO of @eXoZymes, shares a fantastic introduction to the company in this new podcast episode A great entry point for understanding the science, the strategy and the impact behind $EXOZ Give it a listen on your next evening walk! 🎧 https://www.bc-la.org/podcast/episode/1e32e528/revolutionizing-biotechnology-with-exozymes-michael-heltzen-ceo-of-exozymes
0 · Reply
Slack_Capital
Slack_Capital Sep. 30 at 8:48 PM
$EXOZ @eXoZymes is establishing itself as cell-free biomanufacturing's thought leader: - Leadership/Technical committee appointment to BioMade - eXoZymes selected as core industry partner for $9M grant to advance cell-free biomanufacturing - eXoZymes is crafting the language, terminology and standards as first movers (GEN Tech) - Yannick Bombel, NREL, reached out to Tyler Korman after releasing the significance of the tech - Seemingly the only global Exozyme system company - Holds all the core patents and has numerous trade secrets https://exozymes.com/blog/biomade-thought-leaders?utm_campaign=24163114-202509%20BioMADE%20thought%20leadership
0 · Reply
eXoZymes
eXoZymes Sep. 26 at 1:41 PM
0 · Reply
Slack_Capital
Slack_Capital Sep. 25 at 9:57 PM
$EXOZ Just released a snapshot investment report on @eXoZymes 🔬🧪💊 It covers the latest key developments and a speculative roadmap with market cap projections until 2028 https://slack-capital.com/p/exozymes-snapshot-investment-case If you missed my inital report, this post offers a fantastic investment intro
0 · Reply
Slack_Capital
Slack_Capital Sep. 23 at 10:15 PM
$EXOZ sell side looks to be drying up and long-term shareholders are holding tight 🔥 @exozymes is in the final stages of deal negotiations with 3 parties, so when the first commercial agreement lands, the share price could have a dramatic re-rate!
0 · Reply
Slack_Capital
Slack_Capital Sep. 21 at 8:54 PM
$EXOZ Some research into Santelene... Santelene synthesis results should come to light around Jan 2026. This follows suit with NCTs 5 month development timeline. This timing also coincides with eXoZymes’ new biomanufacturing infrastructure coming online, designed to produce 400g of NCT and also be suited to synthesise other compounds such as santalene. Like NCT, santalene is found in trace amounts in nature, making up just 1–3% of sandalwood oil. This oil itself represents just 3–6% of the heartwood mass. To extract 1 kg of pure santalene, around 33–100 litres of sandalwood oil would be required. At today’s prices, that equates to US$83,000–260,000. By comparison, lab suppliers sell pure santalene at US $256–700 per gram, valuing 1 kg at US $256,000–700,000.
1 · Reply
JohnMitchell230
JohnMitchell230 Sep. 21 at 12:38 PM
$EXOZ Energy services cyclicality. Testing key support. Volume decline concerning. Sector headwinds.
0 · Reply
Slack_Capital
Slack_Capital Sep. 19 at 11:17 PM
$EXOZ My estimations for eXoZymes until 2028 2025 year-end State: pre-rev; negotiations disclosed; first supply pilots underway; ND roadshows. Multiple drivers: platform scarcity + “first-deal imminence.” Market cap: $150–300m (rerate on credible deal pipeline) 1H-2026 (Feb–Jun) 3 deals signed (2 nutra incl. NCT, 1 specialty), Sandaline pilot NCT scaled; partner go-to-market locked; launch by Jun-2026. Upfronts/milestones recognised; first small royalty ticks late Q2. Market cap: $0.6–1B 2H-2026 5–7 total deals; 1st license inked. Royalty run-rate building; 2026 rev visibility $10–20m (mix of upfronts/milestones + small royalties). Possibility of MDB Capital shares unlocking to market Market cap: $1–1.6B 2027 10–14 active licensed programs (nutra, pharma, specialty); NCT royalties compounding across multiple brands/geos. NCT analogs: preclinical packages under Option/License (bigger milestones). Annualised revenue potential $50–100m with 70%+ gross margin characteristics. Market cap: $2.5–5B
3 · Reply
Slack_Capital
Slack_Capital Sep. 19 at 10:21 AM
$EXOZ Love to see it! Could the first commerical deal come before the end of the year?
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 10 at 8:12 AM
$EXOZ pm gappers.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 5 at 3:53 PM
$EXOZ Great piece that accurately captures EXOZ's current position. So if you want to refresh your understanding of EXOZ or learn about EXOZ for the first time, this is essential reading. https://beyondspx.com/quote/EXOZ/exoz-unlocking-nature-s-potential-with-ai-engineered-exozymes#analysis
0 · Reply
B2iDigital
B2iDigital Aug. 29 at 8:42 PM
Spartan Capital Securities, LLC and B2i Digital are pleased to announce that eXoZymes (Nasdaq: $EXOZ) Inc. will be a presenting company at the upcoming Spartan Capital Investor Conference on November 3rd, 2025, in New York. The Spartan Capital Investor Conference 2025 is a B2i Digital Featured Conference. Now in its second year, the conference brings together public company executive teams, institutional investors, and thought leaders from across the U.S. capital markets for strategic networking and information exchange. Taking place at the Marriott Marquis Hotel in New York, this premier event will welcome 500+ institutional and high-net-worth investors and feature presentations from 60 public and private growth companies across technology, healthcare, consumer, and other high-opportunity sectors. Attendees can expect main-stage presentations, curated one-on-one meetings, and extensive networking opportunities that connect innovative companies with sophisticated capital. eXoZymes Inc. (Nasdaq: EXOZ) has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature’s own natural processes to produce chemical compounds, enabling the company’s partners to upgrade traditional petro-chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes. Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels. By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing. While the company, eXoZymes Inc., has introduced “exozymes” as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of. Event details and registration for the Spartan Capital Investor Conference 2025 are available at https://b2idigital.com/spartan-capital-investor-conference-2025. B2i Digital is working closely with the outstanding Spartan Capital team, including John D. Lowry (CEO), Kim Monchik (CAO), Stephen Faucetta (Managing Director), and Julia Voss (Executive Assistant), to enhance each presenter’s reach through in-depth digital profiles and targeted outreach. Investors can register to attend: https://www.meetmax.com/sched/event_125183/investor_reg_new.html?attendee_role_id=SPARTAN_INVESTOR_ATT. Learn more about eXoZymes at https://exozymes.com/investor
3 · Reply
FactorModelPro
FactorModelPro Aug. 27 at 4:39 AM
$EXOZ price stabilizing, could attract dip buyers.
1 · Reply
Slack_Capital
Slack_Capital Aug. 11 at 8:42 AM
$EXOZ reminder of the Q2 Investor Call this coming Tuesday at 5pm Register in the link below https://exozymes.com/blog/2025-q2-call?utm_campaign=19006742-202508%20Q2%20earnings%20call&utm_content=342241824&utm_medium=social&utm_source=twitter&hss_channel=tw-1890406768372502528
0 · Reply
Slack_Capital
Slack_Capital Aug. 7 at 10:39 PM
$EXOZ ⚠️ Come join the conversation on a dedicated eXoZymes channel ⚠️ Wasn't able to share the invite link here, so click my Tweet to find the link https://x.com/Slack_Capital/status/1953584106174132367
2 · Reply
Slack_Capital
Slack_Capital Jul. 29 at 11:54 PM
$EXOZ What a powerful announcement from @eXoZymes 🔥 To produce just 4 grams of NCT, you would need 25 kgs of hemp seeds or around 1,600 hemp plants. Not sustainable at all... A 100x production scale-up is already in the pipeline and will be complete in 6 months This is the first of many projects in development https://exozymes.com/blog/nct-breakthrough-purity
0 · Reply
Slack_Capital
Slack_Capital Jul. 25 at 10:52 AM
$EXOZ Link to the AGM meeting at 1pm PST http://www.virtualshareholdermeeting.com/EXOZ2025
0 · Reply